| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 11.47 Billion | USD 19.78 Billion | 5.6% | 2024 |
FrequentlyAsked Questions
The global epilepsy therapeutics market is expected to grow due to increasing prevalence of epilepsy and seizure disorders, rising adoption of novel anti-epileptic drugs, growing advancements in neuromodulation therapies, and expanding research into precision medicine and genetic treatments.
According to a study, the global epilepsy therapeutics market size was worth around USD 11.47 Billion in 2024 and is expected to reach USD 19.78 Billion by 2034.
The global epilepsy therapeutics market is expected to grow at a CAGR of 5.6% during the forecast period.
North America is expected to dominate the epilepsy therapeutics market over the forecast period.
Leading players in the global epilepsy therapeutics market include Amneal Pharmaceuticals LLC, Upsher-Smith Laboratories, LLC., Eisai Co., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis AG, Bausch Health Companies Inc., UCB S.A., and Pfizer Inc, among others.
The report explores crucial aspects of the epilepsy therapeutics market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients